Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF
Status:
Completed
Trial end date:
2020-01-21
Target enrollment:
Participant gender:
Summary
Unlike heart failure with reduced ejection fraction (HFrEF) where several medicines and
devices have been demonstrated to reduce mortality, no such therapies have been identified in
HFpEF. This may be in part due to incomplete understanding of the underlying mechanisms of
HFpEF.
Recently, impaired myocardial blood flow, reduced myocardial energy utilization, and
increased myocardial fibrosis have been postulated to play important pathophysiologic roles
in HFpEF. The investigators and others have demonstrated that HFrEF may be associated with
altered myocardial energy utilization and "energy starvation." However, there are limited
data regarding "energy starvation" in HFpEF and the relationships between myocardial blood
flow, energy utilization, and fibrosis in HFpEF are largely unknown. Therefore, the purposes
of this study are to use non-invasive cardiac imaging techniques to describe cardiac
structure, function, blood flow, energetics, and fibrosis, and the relationships between
these in order to better understand underlying mechanisms in HFpEF.